HPC
ARQT icon

HM Payson & Co’s Arcutis Biotherapeutics ARQT Stock Holding History

HM Payson & Co’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-135
Closed -$3.92K – 1131
2025
Q4 		$3.92K Buy
+135
New +$3.46K ﹤0.01% 999

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HM Payson & Co's ARQT Position: Q1 2026 in Review

HM Payson & Co sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 135 shares — an estimated $3.92K sold.

HM Payson & Co first reported a position in ARQT in Q4 2025 and held it in 1 quarter. The position peaked at $3.92K in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • HM Payson & Co reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • HM Payson & Co sold 135 Arcutis Biotherapeutics shares in Q1 2026, an estimated $3.92K.
  • HM Payson & Co first reported a position in Arcutis Biotherapeutics in Q4 2025 and held it in 1 quarter.
  • HM Payson & Co's Arcutis Biotherapeutics position peaked at $3.92K in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on HM Payson & Co's 13F filing for Q1 2026, filed 13 Apr 2026.